This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
|Articles|November 19, 2009
AAPS 2009 - Innovations : Transformation to Polymorphic Anhydrates
Advertisement
A Joint Presentation of Pharmaceutical Technology and
Young Innovators of 2009: Interviews with AAPS Graduate Student Winners
Transformation to Polymorphic Anhydrates
Subscribe to RSS feed of this series
Ji Yi Khoo
Imperial College London
Category: MANUFACTURING SCIENCE AND ENGINEERING
Pharmaceutical Channel Hydrate: Elucication of its Thermodynamic Stability and Solid-state Phase Transformation to Polymorphic Anhydrates
View Poster Presentation
Related Articles
Winning Presentations
Listen to the Interviews
AAPS President
Dr. Patrick P. DeLuca, president of AAPS, discusses the organization’s programs and commitment to student scientists.
Listen>>
Advertisement
Related to this article
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
France Remains One of Europe’s Leading Biotech Funding Hubs
3
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5